If you are exploring how to set up an amyloidosis center in Latin America, you might be interested in attending our roundtable meeting.
Our independent medical education program is designed to support multidisciplinary teams in establishing and strengthening specialist amyloidosis services, with region-specific insights to reflect real-world challenges and support implementation.
Early and accurate diagnosis, followed by timely initiation of treatment, is essential for improving outcomes in patients with amyloidosis. However, in Latin America, patients often experience significant diagnostic delays, complicated by the limited number of specialized centers equipped to offer coordinated, multidisciplinary care.
To address these urgent challenges, we are running a virtual roundtable meeting to discuss how to overcome challenges in establishing and operating amyloidosis services in the LATAM region.
We will be joined by three amyloidosis experts who have been instrumental in setting up successful amyloidosis services in their respective countries, Brazil, Argentina, and Mexico.
Co-program directors
Alejandra Gonzalez Duarte (Mexico)
Department of Neurology, NYU Grossman School of Medicine & Co- Director, NYU Dysautonomia Center, USA
Bio| Time | Session |
|---|---|
| 10 mins | Welcome and Introduction |
| 30 mins | Session 1: Improving diagnosis and referral pathways |
| 30 mins | Session 2: Optimizing amyloidosis treatment in LATAM |
| 30 mins | Session 3: Building effective multidisciplinary collaboration |
| 15 mins | Session 4: Panel discussion and Q&A |
| 5 mins | Closing remarks |
This roundtable discussion will provide a platform for HCPs to engage directly with expert faculty and peers for specialized guidance and discussions around region-specific challenges to setting up a dedicated service, referring patients to existing centers, and improving multidisciplinary collaboration.
The meeting will be conducted in Spanish and Portuguese, with simultaneous translation available.
This meeting is suitable for learners involved in the diagnosis and management of amyloidosis. Please apply for a place at the roundtable if you have an interest in establishing an amyloidosis service in LATAM.
After taking part in this program, you will be able to:
Neurologists, cardiologists, hematologists, gastroenterologists, orthopedic surgeons, nephrologists, geneticists, physiotherapists, psychologists, pathologists, nurses, and other HCPs involved in diagnosis and management of patients with amyloidosis
Márcia Waddington has a Master’s and PhD in Neurology from FM-UFRJ (Federal University of Rio de Janeiro), and a specialist in Clinical Neurophysiology from SBNC/AMB (Brazilian Society of Clinical Neurophysiology/Brazilian Medical Association). She is a permanent faculty member of the postgraduate program in Clinical Medicine at FM-UFRJ, and Principal Investigator at the Amyloidosis Reference Center, CEPARM, University Hospital of UFRJ. Dr Waddington is also Coordinator of the Amyloidosis Care Pathway at the Américas-Vitória-Samaritano Barra RJ Hospital Complex, and Principal Investigator at the Américas Institute for Research and Education.
Disclosures
Márcia Waddington discloses honoraria/consultation fees from Pfizer, AstraZeneca, Alnylam, Ionis, PTC Therapeutics, Eidos, and Johnson&Johnson.
María Adela Aguirre is a physician with a PhD in Internal Medicine and a member of the Amyloidosis Study Group at Hospital Italiano de Buenos Aires. Since 2010, her work has focused on the care of patients with amyloidosis, along with medical education, clinical research, and innovation aimed at improving the understanding and management of this disease.
María Adela Aguirre has no financial disclosures.
Alejandra González-Duarte is a neurologist and internist, currently working in the Department of Neurology at NYU Grossman School of Medicine as a Carl Seaman Family Clinical Associate Professor of Dysautonomia Treatment and Research, and as Assistant Director of the Dysautonomia Research Laboratory.
Dr. González-Duarte has focused her research and clinical practice on rare autonomic disorders. She is the principal investigator of many trials for ATTR amyloidosis and has published extensive works on this disease. She also participates as principal investigator or co-investigator in studies for other congenital diseases such as familial dysautonomia and congenital insensitivity to pain and anhidrosis. She cares for patients with infectious, inflammatory, and degenerative autonomic disorders.
During the COVID-19 pandemic, Dr. González-Duarte was a supervisor in the emergency department and in-patient hospital care. She published several works on the neurologic and autonomic complications of COVID-19 and manuscripts describing the bioethical challenges in research and clinical attention during the pandemic. Currently, she is working within the Dysautonomia Center to characterize these sequels, avoid further complications, and start several lines of treatment.
She has specialties in internal medicine and neurology, postdoctoral fellowships in neuroinfectious diseases and autonomic nervous system disorders, and a master’s in bioethics. She has been part of the Institutional Review Board of Bioethics and Research for several years.
Disclosures
To be confirmed